Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Inclusion Criteria:

Have histologically documented diagnosis of ovarian, fallopian or peritoneal cancer that is platinum resistant.
Have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal
Greater than or equal to 18 years of age
Have clinically acceptable laboratory screening results
Have an ECOG performance status of 0 or 1
Able to tolerate oral medications

Exclusion Criteria:

Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or diastolic blood pressure greater than 100mmHg); require two or more antihypertensive medications to control hypertension (including ACE inhibitors, beta blockers, calcium channel blockers, or diuretics)
Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater than 470 msec
Have active, acute, or chronic clinically significant infections or bleeding
Have persistent 2+ protein by urinalysis or a history of nephrotic syndrome